CTOs on the Move

Plexium

www.plexium.com

 
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.plexium.com
  • 11494 Sorrento Valley Road
    San Diego, CA USA 92121
  • Phone: 858.263.7491

Executives

Name Title Contact Details
Daniel Sipes
Senior Vice President and Head of Technology Profile

Funding

Plexium raised $28M on 10/17/2019
Plexium raised $35M on 01/19/2021

Similar Companies

Marligen Biosciences

Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

University Technologies International

University Technologies International is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

Alvotech

Alvotech is a fully integrated specialty biopharmaceutical company focused on development and manufacturing of high quality biosimilar medicines.

Pionyr Immunotherapeutics

Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.